Ryan Donnelly

Ryan Donnelly

Auto-generated profile, based on publicly available information

Ryan Donnelly

Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin 4, Ireland; Department of Radiology, St. Vincent's University Hospital, Dublin 4, Ireland; School of Medicine, University College Dublin, Dublin 4, Ireland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in European Radiology
Verified
Journal Article
Open access
PDF file
RDRyan Donnelly
Ryan Donnelly
MMMichael McDermott
Michael McDermott
GMGerry McManus
Gerry McManus
AFAlessandro N. Franciosi
Alessandro N. Franciosi
MKMichael P. Keane
Michael P. Keane
DMDavid Murphy
David Murphy
Background: 18F-Fluorodeoxyglucose (FDG) PET/CT is emerging as a tool in the diagnosis and evaluation of pulmonary sarcoidosis, however, there is limited consensus regarding its diagnostic performance and prognostic value. Method: A meta-analysis was conducted with PubMed, Science Direct, MEDLINE, Scopus, and CENTRAL databases searched up to and including September 2023. 1355 studies were screened, with seventeen (n = 708 patients) suitable based on their assessment of the diagnostic performance or prognostic value of FDG-PET/CT. Study quality was assessed using the QUADAS-2 tool. Forest plots of pooled sensitivity and specificity were generated to assess diagnostic performance. Pooled changes in SUVmax were correlated with changes in pulmonary function tests (PFT). Results: FDG-PET/CT in diagnosing suspected pulmonary sarcoidosis (six studies, n = 400) had a pooled sensitivity of 0.971 (95%CI 0.909–1.000, p = < 0.001) and specificity of 0.873 (95%CI 0.845–0.920)(one study, n = 169). Eleven studies for prognostic analysis (n = 308) indicated a pooled reduction in pulmonary SUVmax of 4.538 (95%CI 5.653–3.453, p = < 0.001) post-treatment. PFTs displayed improvement post-treatment with a percentage increase in predicted forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) of 7.346% (95%CI 2.257–12.436, p = 0.005) and 3.464% (95%CI -0.205–7.132, p = 0.064), respectively. Reduction in SUVmax correlated significantly with FVC (r = 0.644, p < 0.001) and DLCO (r = 0.582, p < 0.001) improvement. Conclusion: In cases of suspected pulmonary sarcoidosis, FDG-PET/CT demonstrated good diagnostic performance and correlated with functional health scores. FDG-PET/CT may help to guide immunosuppression in cases of complex sarcoidosis or where treatment rationalisation is needed. Clinical relevance statement: FDG-PET/CT has demonstrated a high diagnostic performance in the evaluation of suspected pulmonary sarcoidosis with radiologically assessed disease activity correlating strongly with clinically derived pulmonary function tests. Key Points: In diagnosing pulmonary sarcoidosis, FDG-PET/CT had a sensitivity and specificity of 0.971 and 0.873, respectively. Disease activity, as determined by SUVmax, reduced following treatment in all the included studies. Reduction in SUVmax correlated with an improvement in functional vital capacity, Diffusion Capacity of the Lungs for Carbon Monoxide, and subjective health scoring systems.

25 February 2025 in Chest
Verified
Journal Article
Open access
RDRyan Donnelly
Ryan Donnelly
AFAlessandro N Franciosi
Alessandro N Franciosi
SFSarah H. Forde
Sarah H. Forde
MMMichael McDermott
Michael McDermott
MKMichael P Keane
Michael P Keane
CMCormac McCarthy
Cormac McCarthy
Fluoro-2-deoxyglucose-18 (FDG) positron emission tomography (PET/CT) has utility in identifying sites of active sarcoidosis. However, the role of FDG-PET/CT in predicting treatment response and guiding therapy outside of cardiac disease is yet to be completely understood. Do physicians agree on the utility of FDG-PET/CT in sarcoid cases, and do they agree on the appropriate treatment response, based on the associated reports? Physicians respondents were presented with a series of anonymised sarcoidosis case vignettes. The perceived utility of FDG-PET/CT in each case, as well as the ultimate treatment decision following provision of FDG-PET/CT results was assessed. Inter-rater agreement was assessed overall and per case vignette specialty using Gwet's Agreeability Coefficient (AC1). Respondents (n=215) were predominantly respiratory physicians (86.78%) experienced in sarcoidosis management (94.39%), and a third of whom had >20 years' experience (32.66%). Pulmonary sarcoidosis case vignettes had the lowest rates of FDG-PET/CT endorsement among surveyed subspecialties (38 - 64%). Overall inter-rater agreement was assessed among physicians who positively endorsed an FDG-PET/CT. Treatment rationalisation based on FDG-PET/CT report was near-chance agreement for pulmonary AC1=0.178 (N=217, 95% CI 0.125- 0.234, p=0.07) and multisystem AC1=0.296 (N=168, 95% CI 0.066 - 0.477, p=0.41) cases, while agreement was highest for cases of cardiac sarcoidosis AC1=0.797 (N=374, 95% CI 0.759 - 0.838, p=<0.05). Our results indicate a low agreement between physicians regarding their management of pulmonary sarcoidosis following FDG-PET/CT. This highlights a need for further research and clarity over the role of FDG-PET/CT in the therapeutic management of pulmonary sarcoidosis.


3 December 2024 in European Radiology
Verified
Journal Article
Closed access
PDF file
RDRyan Donnelly
Ryan Donnelly
CMCormac McCarthy
Cormac McCarthy
DMDavid J. Murphy
David J. Murphy

14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
RDRyan Donnelly
Ryan Donnelly
AFAlessandro N. Franciosi
Alessandro N. Franciosi
SFSarah Forde
Sarah Forde
MMMichael Mcdermott
Michael Mcdermott
MKMichael P. Keane
Michael P. Keane
CMCormac Mccarthy
Cormac Mccarthy
Background: Fluoro-2-deoxyglucose-18 (FDG) positron emission tomography (PET/CT) is a novel and effective method of identifying sites of active sarcoidosis. However, the role of FDG-PET/CT in predicting treatment response and guiding therapy, is yet to be completely understood. Physician agreement on FDG-PET/CT utility and management was assessed in this publication through a series of sarcoidosis case vignettes. Methods: Survey responders were presented with a series of anonymised sarcoidosis case vignettes. The perceived utility of FDG-PET/CT in each case, as well as the ultimate treatment decision following provision of FDG-PET/CT results was retained. Rater inter-agreement was assessed overall and per case vignette specialty using Krippendorff’s alpha. Results: Responders (n=215) were predominantly respiratory physicians (86.78%) experienced in sarcoidosis management (94.39%), many with >20 years’ experience (32.66%). The overall inter-rater agreement assessment of all cases was poor (α=0.419). Rater agreement when filtered for case subspecialty was also poor for all cases of cardiac (α=0.567), respiratory (α=0.347) and multi-system sarcoidosis (α=0.286). FDG-PET/CT imaging was more frequently endorsed for cardiac than pulmonary cases (83% vs. 47%). Immunosuppression was increased in over 80% of cardiac cases, while current treatment plans were typically maintained for pulmonary cases. Conclusion: Our results indicate a low agreement between respiratory physicians and their management of pulmonary sarcoidosis following FDG-PET/CT. This highlights a need for further research and clarity over the role of FDG-PET/CT in the therapeutic management of pulmonary sarcoidosis.

14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
RDRyan Donnelly
Ryan Donnelly
MDMichael Mc Dermott
Michael Mc Dermott
GMGerry Mc Manus
Gerry Mc Manus
AFAlessandro N. Franciosi
Alessandro N. Franciosi
MKMichael P Keane
Michael P Keane
DMDavid J Murphy
David J Murphy
18F-Fluorodeoxyglucose (FDG) PET/CT is emerging as a tool in the diagnosis and evaluation of thoracic sarcoidosis, however, there is limited consensus regarding its diagnostic performance and prognostic value. A meta-analysis was conducted with publication databases searched up to and including September 2023. 1,355 studies were screened, with 17 (n=708 patients) suitable based on their assessment of diagnostic performance or prognostic value of FDG-PET/CT. Forest plots of pooled sensitivity and specificity were generated to assess diagnostic performance and pooled change in SUVmax. These were correlated with changes in pulmonary function tests (PFTs) and quality-of-life. FDG-PET/CT for the diagnosis of thoracic sarcoidosis (6 studies, n=400) had a pooled sensitivity of. 971 (95%CI 0.909 – 1.000, p=<.001), with a specificity (1 study, n=169) of. 873 (95%CI. 845 –. 920). 11 studies were suitable for prognostic analysis (n=308) with a pooled reduction in pulmonary SUVmax of 4.538 (95%CI 5.653 – 3.453, p=<.001) following treatment. PFTs showed improvement following treatment with an increase in percentage of predicted forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) of 7.346% (95%CI 2.257 – 12.436, p=.005) and 3.464% (95%CI -0.205 – 7.132, p=.064), respectively. Reduction in SUVmax strongly correlated with improvement in FVC (r =.644, p<.001) and DLCO (r =.582, p<.001). QOL indicators improved in 75% of the studies assessed (4 studies, n=116). FDG-PET/CT has a high diagnostic performance in thoracic sarcoidosis. Relative change in FDG-PET/CT SUVmax correlated with improvements in PFTs and QOL indicators and may be useful in guiding treatment response.